• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Landmark Outcomes Study Shows That Repatha ® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent Risks of Heart Attack, Stroke and Coronary Revascularization Were Nominally Reduced by 27 Percent, 21 Percent and 22 Percent, Respectively Patients in Study had History of Heart Attack, Stroke or Symptomatic Peripheral Arterial Disease and Were Treated With Optimized Statin Therapy Amgen to Offer Innovative Refund Contracts in the U.S. Detailed Results Simultaneously Published in the New England Journal of Medicine and Presented at the American College of Cardiology 66th Annual Scientific Session THOUSAND OAKS, Calif.,...
Source: Amgen News Release - March 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Ninds
InitiativeThe mission of the National Institute of Neurological Disorders and Stroke (NINDS) is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. To support this mission, NINDS: Supports and performs basic, translational, and clinical neuroscience research through grants-in-aid, contracts, scientific meetings, and through research in its own laboratories, and clinics. Funds and conducts research training and career development programs to increase basic, translational and clinical neuroscience expertise and ensure a vibrant, talented, a...
Source: PHRMA - March 28, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news